PharmaBoardroom

Public Insurance Coverage for Rare Disease Patients in China:…

Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the findings of the first ever analysis into…

USA: 2 Things the Biden Administration can do Now to Lower Costs…

PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can help lower healthcare costs and why biopharmaceutical companies support…

Top 5 Global CDMOs

As the global pharmaceutical industry continues to grow, so have opportunities for service providers. Over the last few decades, while big pharma…

STADA’s Bold Bets on M&A

After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including…

Securing the Conditions to Secure Our Meds

The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar medicines have on US healthcare today and introduces the ‘Secure…

IFPMA’s Thomas Cueni on why “#TeamVaccines is all of…

Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights the incredible progress of COVID-19…

After Brexit: Focus on the New Pharmaceutical Strategy for Europe

Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler of Sanofi R&D looks at the future of European pharma post-Brexit,…

Building a Health Data Ecosystem in Switzerland

Although Switzerland is ahead of many of its competitors in Europe on levels of healthcare innovation, one potential stumbling block is access to and…